The innovative approach, of BioHC programme, carries a significant potential in engineering design and progress driving in Clinical and Life industries. The tools, techniques, and approaches proposed by the Graduate School are becoming standard in research labs and R&D department. In the coming decades, Nano/Molecular Biotechnology can undoubtedly become the driving force for a new set of products, systems and applications in health sector. It is expected that they will become the basis for a new industrial revolution. But to succeed, this new industry would insert this development in an efficient Product Lifecycle Management (PLM), taking into account both basic, clinical and engineering research, in the framework of iterative steps and feedback loops between bench and bedside, (ie spiral IT algorithms instead of linear ones). Many organizations are going to put the core concept of Systems biology properly into practice by informing their research through the iterative cycle between experimentation and modelling. Systemic modelling and simulation tools should substantially improve the efficiency of this innovative translational programme. This programme should develop both from existing companies, which are investing in innovation; and from completely new companies and start-ups, based on new inventions at the interface between clinical research, chemistry, biotechnology, and material science.
Clinical and Life Sciences industries needing trained people can be divided into two broad categories: those that employ System Biology’s methodology to make end products, and those that create tools, which are sold to, and used by the companies in the first group.
- Large companies such as drug development firms, pharmaceutical industries, and commodity producers beloning to the first category, need people driven by biology questions who want to take computational routes. Their demand is particularly great for people who can analyze data, who approach biology in a quantitative fashion and can integrate information from different areas.
- Small and Medium sized Enterprises (SMEs) in the biotech sector for example, belonging to the latter category, seek to license their tools to larger pharmaceutical firms. There may be opportunities for small and medium enterprises to develop software solutions for companies to handle their big amount of data effectively.
Strong relationships with industry to boost your career prospect.
Besides BioHC Graduate School, during their studies and specially the yearly BioHC Schools, MSc students and Doctorate candidates will make valuable career contacts with companies, at a worldwide level. BioHC graduates and postgraduates could be employed by companies in the fields of: Pharma, Chemical, Biotechonology and Information Technology. They should go on to work for private companies such as Big pharma (Sanofi, BioMérieux, Merial, Novartis, Roche, Pierre Fabre, Dassault Systems, etc.), as well as for Bio/Information technology (Serrono, Sobio, Novadiscovery, Altrabio, Novimmune, Genkyotex, Animascope, etc.) or Research organizations and National health regulatory bodies. With your degree you will end up in R&D (research & development), product design, product development or you will become an independent consultant at the interface between several fields of expertise. Moreover you will have an ideal background to use you broad view on the domain to develop and create new products or even startup completely new companies.